Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis

Background. We conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with multiple sclerosis (MS). Methods. Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature, including...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Multiple sclerosis international Ročník 2022; s. 1 - 13
Hlavní autoři:	Barzegar, Mahdi, Houshi, Shakiba, Sadeghi, Erfan, Hashemi, Mozhgan Sadat, Pishgahi, Ghasem, Bagherieh, Sara, Afshari-Safavi, Alireza, Mirmosayyeb, Omid, Shaygannejad, Vahid, Zabeti, Aram
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Egypt Hindawi 21.09.2022 John Wiley & Sons, Inc
Témata:	Analysis Biological response modifiers Cohort analysis Coronaviruses COVID-19 Development and progression Disease susceptibility Disease transmission Health aspects Hospitalization Immunotherapy Infections Interferon Medical research Medicine, Experimental Meta-analysis Monoclonal antibodies Mortality Multiple sclerosis Pandemics Pharmacovigilance Population Review Severe acute respiratory syndrome coronavirus 2 Software Systematic review Iran United States > US Europe Spain
ISSN:	2090-2654, 2090-2662
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Background. We conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with multiple sclerosis (MS). Methods. Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature, including reference lists and conference abstracts, were searched from December 1, 2019, to July 26, 2021. We included cross-sectional, case-control, and cohort studies assessing the association of DMTs with risk of contracting COVID-19 or its outcomes in MS patients on univariate or multivariate regression analyses. We conducted a network meta-analysis (NMA) to compare the risk of COVID-19 and developing severe infection across DMTs. Results. Out of the initial 3893 records and 1883 conference abstracts, a total of 10 studies were included. Pairwise comparisons showed that none of the DMTs meaningfully affect the risk of acquiring infection. There was significant total heterogeneity and inconsistency across this NMA. In comparison with no DMT, dimethyl fumarate (0.62 (0.42, 0.93)), fingolimod (0.55 (0.32, 0.94)), natalizumab (0.50 (0.31, 0.81)), and interferon (0.42 (0.22, 0.79)) were associated with a decreased risk of severe COVID-19; but, rituximab was observed to increase the risk (1.94 (1.20, 3.12)). Compared to rituximab or ocrelizumab, all DMTs were associated with a decreased risk. Pairwise comparisons showed no differences across other DMTs. Interferon and rituximab were associated with the lowest and highest risks of severe COVID-19. Conclusion. Our study showed an increased risk of severe COVID-19 in patients on rituximab and ocrelizumab. No association with COVID-19 severity across other DMTs was observed.
AbstractList	Background. We conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with multiple sclerosis (MS). Methods. Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature, including reference lists and conference abstracts, were searched from December 1, 2019, to July 26, 2021. We included cross-sectional, case-control, and cohort studies assessing the association of DMTs with risk of contracting COVID-19 or its outcomes in MS patients on univariate or multivariate regression analyses. We conducted a network meta-analysis (NMA) to compare the risk of COVID-19 and developing severe infection across DMTs. Results. Out of the initial 3893 records and 1883 conference abstracts, a total of 10 studies were included. Pairwise comparisons showed that none of the DMTs meaningfully affect the risk of acquiring infection. There was significant total heterogeneity and inconsistency across this NMA. In comparison with no DMT, dimethyl fumarate (0.62 (0.42, 0.93)), fingolimod (0.55 (0.32, 0.94)), natalizumab (0.50 (0.31, 0.81)), and interferon (0.42 (0.22, 0.79)) were associated with a decreased risk of severe COVID-19; but, rituximab was observed to increase the risk (1.94 (1.20, 3.12)). Compared to rituximab or ocrelizumab, all DMTs were associated with a decreased risk. Pairwise comparisons showed no differences across other DMTs. Interferon and rituximab were associated with the lowest and highest risks of severe COVID-19. Conclusion. Our study showed an increased risk of severe COVID-19 in patients on rituximab and ocrelizumab. No association with COVID-19 severity across other DMTs was observed. We conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with multiple sclerosis (MS). Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature, including reference lists and conference abstracts, were searched from December 1, 2019, to July 26, 2021. We included cross-sectional, case-control, and cohort studies assessing the association of DMTs with risk of contracting COVID-19 or its outcomes in MS patients on univariate or multivariate regression analyses. We conducted a network meta-analysis (NMA) to compare the risk of COVID-19 and developing severe infection across DMTs. Out of the initial 3893 records and 1883 conference abstracts, a total of 10 studies were included. Pairwise comparisons showed that none of the DMTs meaningfully affect the risk of acquiring infection. There was significant total heterogeneity and inconsistency across this NMA. In comparison with no DMT, dimethyl fumarate (0.62 (0.42, 0.93)), fingolimod (0.55 (0.32, 0.94)), natalizumab (0.50 (0.31, 0.81)), and interferon (0.42 (0.22, 0.79)) were associated with a decreased risk of severe COVID-19; but, rituximab was observed to increase the risk (1.94 (1.20, 3.12)). Compared to rituximab or ocrelizumab, all DMTs were associated with a decreased risk. Pairwise comparisons showed no differences across other DMTs. Interferon and rituximab were associated with the lowest and highest risks of severe COVID-19. Our study showed an increased risk of severe COVID-19 in patients on rituximab and ocrelizumab. No association with COVID-19 severity across other DMTs was observed. We conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with multiple sclerosis (MS).BackgroundWe conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with multiple sclerosis (MS).Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature, including reference lists and conference abstracts, were searched from December 1, 2019, to July 26, 2021. We included cross-sectional, case-control, and cohort studies assessing the association of DMTs with risk of contracting COVID-19 or its outcomes in MS patients on univariate or multivariate regression analyses. We conducted a network meta-analysis (NMA) to compare the risk of COVID-19 and developing severe infection across DMTs.MethodsAvailable studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature, including reference lists and conference abstracts, were searched from December 1, 2019, to July 26, 2021. We included cross-sectional, case-control, and cohort studies assessing the association of DMTs with risk of contracting COVID-19 or its outcomes in MS patients on univariate or multivariate regression analyses. We conducted a network meta-analysis (NMA) to compare the risk of COVID-19 and developing severe infection across DMTs.Out of the initial 3893 records and 1883 conference abstracts, a total of 10 studies were included. Pairwise comparisons showed that none of the DMTs meaningfully affect the risk of acquiring infection. There was significant total heterogeneity and inconsistency across this NMA. In comparison with no DMT, dimethyl fumarate (0.62 (0.42, 0.93)), fingolimod (0.55 (0.32, 0.94)), natalizumab (0.50 (0.31, 0.81)), and interferon (0.42 (0.22, 0.79)) were associated with a decreased risk of severe COVID-19; but, rituximab was observed to increase the risk (1.94 (1.20, 3.12)). Compared to rituximab or ocrelizumab, all DMTs were associated with a decreased risk. Pairwise comparisons showed no differences across other DMTs. Interferon and rituximab were associated with the lowest and highest risks of severe COVID-19.ResultsOut of the initial 3893 records and 1883 conference abstracts, a total of 10 studies were included. Pairwise comparisons showed that none of the DMTs meaningfully affect the risk of acquiring infection. There was significant total heterogeneity and inconsistency across this NMA. In comparison with no DMT, dimethyl fumarate (0.62 (0.42, 0.93)), fingolimod (0.55 (0.32, 0.94)), natalizumab (0.50 (0.31, 0.81)), and interferon (0.42 (0.22, 0.79)) were associated with a decreased risk of severe COVID-19; but, rituximab was observed to increase the risk (1.94 (1.20, 3.12)). Compared to rituximab or ocrelizumab, all DMTs were associated with a decreased risk. Pairwise comparisons showed no differences across other DMTs. Interferon and rituximab were associated with the lowest and highest risks of severe COVID-19.Our study showed an increased risk of severe COVID-19 in patients on rituximab and ocrelizumab. No association with COVID-19 severity across other DMTs was observed.ConclusionOur study showed an increased risk of severe COVID-19 in patients on rituximab and ocrelizumab. No association with COVID-19 severity across other DMTs was observed.
Audience	Academic
Author	Hashemi, Mozhgan Sadat Barzegar, Mahdi Shaygannejad, Vahid Afshari-Safavi, Alireza Zabeti, Aram Houshi, Shakiba Sadeghi, Erfan Mirmosayyeb, Omid Pishgahi, Ghasem Bagherieh, Sara
AuthorAffiliation	4 Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran 3 Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Sciences, Isfahan, Iran 6 Department of Neurology and Rehabilitation Medicine, Waddell center in Multiple Sclerosis, University of Cincinnati, Cincinnati, OH, USA 1 Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran 2 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 5 Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran
AuthorAffiliation_xml	– name: 1 Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran – name: 6 Department of Neurology and Rehabilitation Medicine, Waddell center in Multiple Sclerosis, University of Cincinnati, Cincinnati, OH, USA – name: 3 Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Sciences, Isfahan, Iran – name: 4 Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran – name: 5 Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran – name: 2 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Author_xml	– sequence: 1 givenname: Mahdi orcidid: 0000-0002-6578-0250 surname: Barzegar fullname: Barzegar, Mahdi organization: Isfahan Neurosciences Research CenterIsfahan University of Medical SciencesIsfahanIranmui.ac.ir – sequence: 2 givenname: Shakiba orcidid: 0000-0002-8245-4553 surname: Houshi fullname: Houshi, Shakiba organization: Isfahan Neurosciences Research CenterIsfahan University of Medical SciencesIsfahanIranmui.ac.ir – sequence: 3 givenname: Erfan orcidid: 0000-0002-3873-8006 surname: Sadeghi fullname: Sadeghi, Erfan organization: Department of Biostatistics and EpidemiologyFaculty of HealthIsfahan University of Medical SciencesIsfahanIranmui.ac.ir – sequence: 4 givenname: Mozhgan Sadat orcidid: 0000-0001-7388-7448 surname: Hashemi fullname: Hashemi, Mozhgan Sadat organization: Students’ Scientific Research CenterTehran University of Medical SciencesTehranIrantums.ac.ir – sequence: 5 givenname: Ghasem orcidid: 0000-0003-2349-881X surname: Pishgahi fullname: Pishgahi, Ghasem organization: Students’ Scientific Research CenterTehran University of Medical SciencesTehranIrantums.ac.ir – sequence: 6 givenname: Sara orcidid: 0000-0002-1827-9164 surname: Bagherieh fullname: Bagherieh, Sara organization: Isfahan Neurosciences Research CenterIsfahan University of Medical SciencesIsfahanIranmui.ac.ir – sequence: 7 givenname: Alireza orcidid: 0000-0002-2080-946X surname: Afshari-Safavi fullname: Afshari-Safavi, Alireza organization: Department of Biostatistics and EpidemiologyFaculty of HealthNorth Khorasan University of Medical SciencesBojnurdIrannkums.ac.ir – sequence: 8 givenname: Omid orcidid: 0000-0002-3756-2985 surname: Mirmosayyeb fullname: Mirmosayyeb, Omid organization: Isfahan Neurosciences Research CenterIsfahan University of Medical SciencesIsfahanIranmui.ac.ir – sequence: 9 givenname: Vahid orcidid: 0000-0002-9732-4153 surname: Shaygannejad fullname: Shaygannejad, Vahid organization: Isfahan Neurosciences Research CenterIsfahan University of Medical SciencesIsfahanIranmui.ac.ir – sequence: 10 givenname: Aram orcidid: 0000-0002-0424-7460 surname: Zabeti fullname: Zabeti, Aram organization: Department of Neurology and Rehabilitation MedicineWaddell center in Multiple SclerosisUniversity of CincinnatiCincinnatiOHUSAuc.edu
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36187599$$D View this record in MEDLINE/PubMed
BookMark	eNp9kl1v0zAUhiM0xMbYHdfIEhJCgmyO8-VwgVR1fExaGaKDW8txTpoz3LjETqv-Iv4mzlrKOgHxRfzxvK_t4_dxcNCaFoLgaURPoyhNzxhl7KyIOedR_CA4YrSgIcsydrDrp8lhcGLtDfVfSlnO40fBYZxFPE-L4ij4ObLWKJQOTUtMTc7RgrQQTkyF9RrbGbluoJMLBEtW6Boyvvp2cR5GBZn2VsHCYYka3ZrItiJTWEI3DLAln70ltG6rmvTa4UIDmSoNnbFo35ARma6tg7kHFfkCS4TVrcsncCvTfScTcDIctVKvPf4keFhLbeFk-z8Ovr5_dz3-GF5efbgYjy5DleSZC1lcKFqxEgBSnsU154onMq_jkpcFhTRLYlYWdZlnZZEBB1lHearKKilVlFU0jY-DtxvfRV_OoVL-Cp3UYtHhXHZrYSSK_ZUWGzEzS1GkURHHmTd4uTXozI8erBNz9IXSWrZgeitY7h-G8ZjmHn1-D70xfecvvKFYwook_UPNpAaBbW38vmowFSNPpZxG-eB1-hfKtwrmqHxoavTze4IXdwQNSO0aa3Q_BMHug8_uVmRXit8Z8sDrDaD8w9oO6h0SUTGkVAwpFduUepzdwxW62_z5E6P-l-jVRtRgW8kV_n-LX10g9mg
CitedBy_id	crossref_primary_10_1177_20552173241248293 crossref_primary_10_3389_fphar_2023_1264842 crossref_primary_10_1080_1744666X_2023_2248391 crossref_primary_10_2147_DDDT_S236926 crossref_primary_10_4274_jmsr_galenos_2024_2024_3_2
Cites_doi	10.3201/eid1002.030482 10.1212/NXI.0000000000001001 10.1016/j.cytogfr.2014.07.015 10.1128/JVI.00985-20 10.1016/S2665-9913(20)30270-8 10.1001/jamaneurol.2021.0688 10.2139/ssrn.3801769 10.1002/acn3.51408 10.1111/ene.14690 10.1038/nri888 10.1001/jamanetworkopen.2018.4169 10.1002/acn3.51314 10.3389/fimmu.2017.00873 10.1136/annrheumdis-2021-220418 10.1212/WNL.0000000000007262 10.1126/science.abd4585 10.1016/j.clim.2008.01.011 10.1001/jama.2020.2648 10.1111/ene.14990 10.1016/j.msard.2020.102472 10.1007/s40263-020-00756-y 10.1002/ana.26028 10.1016/S2213-2600(20)30566-X 10.1007/s10072-020-04519-x 10.1002/ana.20859 10.1038/s41577-020-0308-3 10.1001/jamaneurol.2019.3365 10.1056/NEJMoa2023184 10.1371/journal.pmed.1000097 10.1038/nrneurol.2016.21 10.1038/s41582-020-0385-8 10.1136/annrheumdis-2020-219498 10.1099/vir.0.061911-0 10.1097/BOR.0b013e3282f5e08d 10.1212/NXI.0000000000000761 10.1128/CMR.14.4.778-809.2001 10.1016/j.clim.2011.04.005 10.1016/j.msard.2021.103153 10.1016/j.msard.2020.102195 10.1007/s40263-021-00804-1 10.1007/s10654-010-9491-z 10.1177/1352458519851981 10.1007/s10072-021-05750-w 10.1212/NXI.0000000000000432 10.1080/07853890.2021.1890329 10.1177/1756285615601933 10.1186/s13054-020-03048-5 10.1016/S2665-9913(21)00059-X 10.1080/21645515.2021.1971920 10.1002/9781119536604
ContentType	Journal Article
Copyright	Copyright © 2022 Mahdi Barzegar et al. COPYRIGHT 2022 John Wiley & Sons, Inc. Copyright © 2022 Mahdi Barzegar et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2022 Mahdi Barzegar et al. 2022
Copyright_xml	– notice: Copyright © 2022 Mahdi Barzegar et al. – notice: COPYRIGHT 2022 John Wiley & Sons, Inc. – notice: Copyright © 2022 Mahdi Barzegar et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2022 Mahdi Barzegar et al. 2022
DBID	RHU RHW RHX AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1155/2022/9388813
DatabaseName	Hindawi Publishing Complete Hindawi Publishing Subscription Journals Hindawi Publishing Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database PubMed MEDLINE - Academic CrossRef
Database_xml	– sequence: 1 dbid: RHX name: Hindawi Publishing Open Access url: http://www.hindawi.com/journals/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Public Health
EISSN	2090-2662
Editor	Patti, Francesco
Editor_xml	– sequence: 1 givenname: Francesco surname: Patti fullname: Patti, Francesco
EndPage	13
ExternalDocumentID	PMC9519336 A720580177 36187599 10_1155_2022_9388813
Genre	Journal Article Review
GeographicLocations	Iran United States--US Europe Spain
GeographicLocations_xml	– name: Iran – name: Spain – name: United States--US – name: Europe
GrantInformation_xml	– fundername: Chugai – fundername: Genentech – fundername: National Institutes of Health – fundername: Biogen – fundername: MedImmune – fundername: PCORI
GroupedDBID	--- 188 4.4 53G 5VS 7X7 8FI 8FJ AAFWJ AAJEY ABDBF ABUWG ADBBV ADRAZ AFKRA AFPKN AINHJ ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV BENPR CCPQU EBD EBS ESX FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW ITC KQ8 M48 M~E OK1 PIMPY RHU RHW RHX RNS RPM TUS UKHRP 0R~ 24P AAMMB AAYXX ACCMX ACUHS AEFGJ AFFHD AGXDD AIDQK AIDYY ALUQN CITATION H13 PGMZT PHGZM PHGZT 2UF ALIPV EJD IL9 NPM UZ5 3V. 7XB 8FK AZQEC COVID DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c476t-239c0d2beee5863f88c84a7f3b8b90e56432b9fb76b96e8eaf175cbd4bc16d053
IEDL.DBID	PIMPY
ISICitedReferencesCount	11
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000864033500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2090-2654
IngestDate	Tue Nov 04 02:07:05 EST 2025 Thu Oct 02 06:15:40 EDT 2025 Tue Oct 07 07:02:56 EDT 2025 Tue Nov 11 10:55:52 EST 2025 Tue Nov 04 18:16:28 EST 2025 Thu May 22 21:26:56 EDT 2025 Mon Jul 21 05:57:39 EDT 2025 Sat Nov 29 02:54:09 EST 2025 Tue Nov 18 22:26:29 EST 2025 Sun Jun 02 19:22:09 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Language	English
License	This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 Copyright © 2022 Mahdi Barzegar et al.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c476t-239c0d2beee5863f88c84a7f3b8b90e56432b9fb76b96e8eaf175cbd4bc16d053
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Academic Editor: Francesco Patti
ORCID	0000-0002-0424-7460 0000-0002-3756-2985 0000-0002-1827-9164 0000-0002-8245-4553 0000-0001-7388-7448 0000-0002-9732-4153 0000-0003-2349-881X 0000-0002-2080-946X 0000-0002-6578-0250 0000-0002-3873-8006
OpenAccessLink	https://www.proquest.com/publiccontent/docview/2720242945?pq-origsite=%requestingapplication%
PMID	36187599
PQID	2720242945
PQPubID	4727247
PageCount	13
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_9519336 proquest_miscellaneous_2720928307 proquest_journals_2720242945 gale_infotracmisc_A720580177 gale_infotracacademiconefile_A720580177 gale_healthsolutions_A720580177 pubmed_primary_36187599 crossref_primary_10_1155_2022_9388813 crossref_citationtrail_10_1155_2022_9388813 hindawi_primary_10_1155_2022_9388813
PublicationCentury	2000
PublicationDate	2022-09-21
PublicationDateYYYYMMDD	2022-09-21
PublicationDate_xml	– month: 09 year: 2022 text: 2022-09-21 day: 21
PublicationDecade	2020
PublicationPlace	Egypt
PublicationPlace_xml	– name: Egypt – name: New York
PublicationTitle	Multiple sclerosis international
PublicationTitleAlternate	Mult Scler Int
PublicationYear	2022
Publisher	Hindawi John Wiley & Sons, Inc
Publisher_xml	– name: Hindawi – name: John Wiley & Sons, Inc
References	45 46 47 Organization WH (3) 48 49 50 J. A. Sparks (44) 2021; 80 51 52 53 10 11 12 13 14 15 16 17 18 19 1 4 5 6 7 8 9 20 21 22 23 24 25 26 27 28 29 M. Barzegar (2) 2011 P. Bastard (31) 2020; 370 30 32 33 34 35 36 37 38 39 40 41 42 43
References_xml	– ident: 27 doi: 10.3201/eid1002.030482 – ident: 7 doi: 10.1212/NXI.0000000000001001 – ident: 25 doi: 10.1016/j.cytogfr.2014.07.015 – ident: 30 doi: 10.1128/JVI.00985-20 – ident: 46 doi: 10.1016/S2665-9913(20)30270-8 – ident: 17 doi: 10.1001/jamaneurol.2021.0688 – ident: 19 doi: 10.2139/ssrn.3801769 – ident: 22 doi: 10.1002/acn3.51408 – ident: 15 doi: 10.1111/ene.14690 – ident: 24 doi: 10.1038/nri888 – ident: 48 doi: 10.1001/jamanetworkopen.2018.4169 – ident: 16 doi: 10.1002/acn3.51314 – ident: 26 doi: 10.3389/fimmu.2017.00873 – volume: 80 start-page: 1137 issue: 9 year: 2021 ident: 44 article-title: Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry publication-title: Annals of the Rheumatic Diseases doi: 10.1136/annrheumdis-2021-220418 – ident: 37 doi: 10.1212/WNL.0000000000007262 – ident: 29 doi: 10.1126/science.abd4585 – ident: 49 doi: 10.1016/j.clim.2008.01.011 – ident: 1 doi: 10.1001/jama.2020.2648 – ident: 20 doi: 10.1111/ene.14990 – ident: 13 doi: 10.1016/j.msard.2020.102472 – ident: 42 doi: 10.1007/s40263-020-00756-y – ident: 18 doi: 10.1002/ana.26028 – ident: 35 doi: 10.1016/S2213-2600(20)30566-X – ident: 14 doi: 10.1007/s10072-020-04519-x – ident: 39 doi: 10.1002/ana.20859 – ident: 50 doi: 10.1038/s41577-020-0308-3 – ident: 5 doi: 10.1001/jamaneurol.2019.3365 – ident: 33 doi: 10.1056/NEJMoa2023184 – ident: 10 doi: 10.1371/journal.pmed.1000097 – ident: 4 doi: 10.1038/nrneurol.2016.21 – ident: 41 doi: 10.1038/s41582-020-0385-8 – ident: 45 doi: 10.1136/annrheumdis-2020-219498 – ident: 28 doi: 10.1099/vir.0.061911-0 – ident: 52 doi: 10.1097/BOR.0b013e3282f5e08d – ident: 40 doi: 10.1212/NXI.0000000000000761 – ident: 23 doi: 10.1128/CMR.14.4.778-809.2001 – ident: 47 doi: 10.1016/j.clim.2011.04.005 – ident: 21 doi: 10.1016/j.msard.2021.103153 – ident: 8 doi: 10.1016/j.msard.2020.102195 – ident: 9 doi: 10.1007/s40263-021-00804-1 – ident: 11 doi: 10.1007/s10654-010-9491-z – ident: 36 doi: 10.1177/1352458519851981 – volume: 370 start-page: 6515 year: 2020 ident: 31 article-title: Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 publication-title: Science (New York, NY) doi: 10.1126/science.abd4585 – ident: 53 doi: 10.1007/s10072-021-05750-w – ident: 38 doi: 10.1212/NXI.0000000000000432 – ident: 34 doi: 10.1080/07853890.2021.1890329 – ident: 51 doi: 10.1177/1756285615601933 – ident: 32 doi: 10.1186/s13054-020-03048-5 – ident: 43 doi: 10.1016/S2665-9913(21)00059-X – ident: 6 doi: 10.1080/21645515.2021.1971920 – year: 2011 ident: 2 article-title: Factors associated with COVID-19 susceptibility and severity in patients with multiple sclerosis: a systematic review – ident: 3 article-title: Situation reports – ident: 12 doi: 10.1002/9781119536604
SSID	ssj0000502783
Score	2.270604
SecondaryResourceType	review_article
Snippet	Background. We conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in... We conducted this study to assess the effect of disease-modifying therapies (DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with...
SourceID	pubmedcentral proquest gale pubmed crossref hindawi
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1
SubjectTerms	Analysis Biological response modifiers Cohort analysis Coronaviruses COVID-19 Development and progression Disease susceptibility Disease transmission Health aspects Hospitalization Immunotherapy Infections Interferon Medical research Medicine, Experimental Meta-analysis Monoclonal antibodies Mortality Multiple sclerosis Pandemics Pharmacovigilance Population Review Severe acute respiratory syndrome coronavirus 2 Software Systematic review
SummonAdditionalLinks	– databaseName: Hindawi Publishing Open Access dbid: RHX link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fi9QwEA96KAgi_re6aoQTHyRcmzZt4tty53GCux7uKftWmmTKFaR7XHdP_ER-TTNNtlxPRR9DJk3amWlmMjO_ELIrLbfOSohZXeQ1yxLgrEo5MAtQgbEmBeg5_bGYz-VyqY4DSFL3ewjf7XbonvM9lTpXDW-nvS4FCu_no-VwlBILDJ9hLJnHKmY8F9k2xf3K8NHmE37BN0_R-f3e_MnEvJopeWnrObxL7gSbkU49k--Ra9DeJ7f9gRv1dUQPyM9LH5quanrgIy9strJNX8tET_pSK-cZUzx8pfufvn44YImii03X57b0abI_aNVaugAn4dhoWnrskVfDqFlIQKQLtxT3kk33jk7pYsCDpj7Y0D9l7lPM6QzWFduinzwkXw7fn-wfsXALAzNZka8ZT5WJLdcAIGSe1lIamVVFnWqpVQzCmTRcq1oXuVY5SKhqZ5EYbTNtktw6HX9EdtpVC08IFanRQoM0wplhUGVVldhEp7V1ZmItZBKRt1v2lCZAlONNGd_K3lURokRmloGZEXk9UJ95aI6_0L1ETpe-sHTQ6HJa8Fi4DbooIvKmp0CddvOZKpQmuFUjOtaIcjKidLpoRt27QZr-saLJVtTK8MvoSgyIO3tJZSIir4ZunADT4FpYbTyNQsg2N9NjL5nDRGmeON9TqYgUI5kdCBBIfNzTNqc9oLhCMz7Nn_7f6p-RW9jEpBmeTMjO-nwDz8kNc7FuuvMXvWr-Av9aM_E priority: 102 providerName: Hindawi Publishing
Title	Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis
URI	https://dx.doi.org/10.1155/2022/9388813 https://www.ncbi.nlm.nih.gov/pubmed/36187599 https://www.proquest.com/docview/2720242945 https://www.proquest.com/docview/2720928307 https://pubmed.ncbi.nlm.nih.gov/PMC9519336
Volume	2022
WOSCitedRecordID	wos000864033500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2090-2662 dateEnd: 20240131 omitProxy: false ssIdentifier: ssj0000502783 issn: 2090-2654 databaseCode: 7X7 dateStart: 20130101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2090-2662 dateEnd: 20240131 omitProxy: false ssIdentifier: ssj0000502783 issn: 2090-2654 databaseCode: BENPR dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2090-2662 dateEnd: 20240131 omitProxy: false ssIdentifier: ssj0000502783 issn: 2090-2654 databaseCode: PIMPY dateStart: 20130101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2090-2662 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000502783 issn: 2090-2654 databaseCode: 24P dateStart: 20100101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ZbxMxELZoAlIlxE0JhGCkIh6Qlb28a_OCQg-1EglRU6rwtFofq66ENqVJQPwi_iYe21m6iOOFl0iJJ7E3Ho9nPN98RmiXqUgZLyEgZZaWJAl1RIo40kRpXWipZKy1nel32WTC5nM-9eXRSw-r3NhEa6gd2zPgto0RHqqFhBPzIWQPzebCE_rm4jOBO6Qg1-ov1NhCXSDeYh3UnR6Ppx-bM5eAQp4Nks5RwAMSpTTZYOEphWOAaMhjExKGcWuX8rb6xjlEyV-r3_miv0Iqr-xRh7f_79PdQbe8r4pHTrnuomu6voduuoM-7OqX7qPvVyYYL0q87zI-ZLxQla2hwqe2xMtE5BgOffHe-7PjfRJyPFsvLabGwnO_4aJWeKbNyoI3VY2njvHVf2vsgY94ZoZi_rNq-RqP8KzhocYuyWF_ZeKg7XisVwXZsK48QB8OD073joi__YHIJEtXJIq5DFQktNaUpXHJmGRJkZWxYIIHmhpXKhK8FFkqeKqZLkrjCUmhEiHDVBnb8hB16kWtHyFMYymo0ExS4_7pIimKUIUiLpVxT0vKwh56tZntXHpqdLih41NuQyRKc9CN3OtGD71opC8cJcgf5J6B4uSuoLWxJPnIzC41jkGW9dBLKwG2xPQnC18SYUYNrFwtyX5L0tgA2Wre9cr5jxH1N9qXe1O1zH8qWw89b5qhA4Df1XqxdjIcqOJMTztO0ZuO4jQ0MS_nPZS1lkAjAATm7Za6OrdE5hzChzh9_PdhPUHb8BAA0onCPuqsLtf6Kbouv6yq5eUAbWXzzL6yAeq-PZhMTwZ-3ZtPT47mPwDCsmYU
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw1JoGCCTE_VIozEibeEDWEidOYiSEqpVp1doyqQX1LST2iRYJpWNpmfZFvPGN-MRJWBCXpz3wGPk0Po2Pz_1CyHakuTZagsOyMMiY7wJniceBaYAElFYeQHXS43A6jRYLebRBvje1MJhW2fDEilHrpUIf-S7GC404kb54e_KF4dQojK42IzQsWRzC-Zkx2co3o6E53x3O99_N9w5YPVWAKT8MVox7UjmapwAgosDLokhFfhJmXhql0gFhRDRPZZaGQSoDiCDJjIRVqfZT5QbawSkRhuVfMaiEmEIWLsLWp-MIjONhUJs70mE8EH6Tay8Euhn4rvSMyel6HSlYy4Jrx2iFn-W_03V_Tdm8IAP3b_9vX-8OuVVr23Rgr8ddsgHFPXLTuiqprcC6T75dIFG6zOjQxqzYZKnzqgqMzqsitRxKim5ruvf-42jIXEln67LKCqoSjM9pUmg6A8Mb8CEv6JHtWVv_alKnbtKZQcWcSl6-pgM6aztpUxumqd4ytcn5dAKrhDV9Yx6QD5fyrR6SzWJZwGNChadSkUKkhFFgIfGTxNVu6mXaKNiZiNweedXQU6zq5u44Y-RzXBl5QsRIfXFNfT2y00Kf2KYmf4DbQtKMbUluywvjgaEmYVSbMOyRlxUEckOzn0rqog6DNfYV60D2O5CGi6nO8nZN_v_AqN_Qd1wz2zL-Sdw98qJdxg0wgbCA5drCSGx2Z3Z6ZK9Su5EXuMZql7JHws4lawGwBXt3pciPq1bsEg0gL3jyd7S2yPWD-WQcj0fTw6fkBv4hTDnibp9srk7X8IxcVV9XeXn6vOInlHy67Cv4A_2rszU
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw1JrGRUiI-6VQmJE28YCsJnYcx0gIVSsT1dZSqWPqW0hsR4uE0rG0TPsi_oGvwydOwoK4PO2Bx8insRuf-xWh7UhTbbUEj2QizEjgG0oSRg3RxiRGacWMqW76QEyn0WIhZxvoe1MLA2mVDU-sGLVeKvCRDyBeaMWJDPggq9MiZqO9tydfCEyQgkhrM07Doci-OT-z5lv5Zjyyd71D6d67w933pJ4wQFQgwhWhTCpP09QYw6OQZVGkoiARGUujVHqGW3FNU5mlIkxlaCKTZFbaqlQHqfJD7cHECMv-rwjGBIyNEAvR-nc8DjE9CHBTT3qEhjxo8u45B5cDHUhmzU-fdSRiLReuHYNFfpb_Tu_9NX3zgjzcu_0_f8k76FatheOhI5u7aMMU99BN58LErjLrPvp2AXXxMsMjF8sik6XOq-owfFgVr-WmxODOxrsfjsYj4ks8X5dVtlCVeHyOk0LjubE8Ax7yAs9cL9v6V5M6pRPP7VHsDeXlazzE87bDNnbhm-otU5e0jydmlZCmn8wD9PFSvtVDtFksC_MYYc5UylMTKW4VW5MESeJrP2WZtop3xiO_h141uBWruuk7zB75HFfGH-cxYGJcY2IP7bTQJ67ZyR_gtgBNY1eq2_LIeGgxi1uVR4geellBAJe0-6mkLvawp4Z-Yx3IfgfScjfVWd6uSeEfJ-o3uB7XTLiMfyJ6D71ol2EDSCwszHLtYCQ0wbM7PXJk1W7EQt9a81L2kOgQXAsArdm7K0V-XLVol2AYsfDJ34-1ha5byosPxtP9p-gG_B_IRKJ-H22uTtfmGbqqvq7y8vR5xVow-nTZFPgDiIi76Q
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+Disease-Modifying+Therapies+with+COVID-19+Susceptibility+and+Severity+in+Patients+with+Multiple+Sclerosis%3A+A+Systematic+Review+and+Network+Meta-Analysis&rft.jtitle=Multiple+sclerosis+international&rft.au=Barzegar%2C+Mahdi&rft.au=Shakiba+Houshi&rft.au=Sadeghi%2C+Erfan&rft.au=Mozhgan+Sadat+Hashemi&rft.date=2022-09-21&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=2090-2654&rft.eissn=2090-2662&rft.volume=2022&rft_id=info:doi/10.1155%2F2022%2F9388813&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2090-2654&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2090-2654&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2090-2654&client=summon